Catalent announces biologics development

A biologics development and manufacturing facility currently under construction near Oxford, UK, has been acquired by Catalent Pharma Solutions from the Vaccine Manufacturing and Innovation Centre (VMIC).  

A total of £120 million ($160 million) is expected to be spent on completing the construction of the facility and equipping it with the most advanced modalities for the development and manufacture of biologic therapies and vaccines, including mRNA, proteins and other advanced technologies.

In addition to employing more than 400 people, the new facility will support public and private organizations seeking to develop and manufacture biotherapeutics.

“This acquisition allows Catalent to collaborate with the rich academic and biomedical science community centered around Oxford, with its world-class talent, and will result in a facility that provides opportunities to transform innovation into real treatments for patients across the UK, Europe and beyond,” said Mike Riley, president of Catalent Biotherapeutics.

Follow us:

Share this article:

Share on linkedin
LinkedIn

Sign Up to our newsletter

Sign up to our newsletter to stay up to date with the latest industry news 

At Easyfairs, we take your privacy seriously and will only use the information we collect or receive about you in accordance with our privacy policy. If you change your mind you can unsubscribe at any time.